In addition to the FLT3 mutation, the NRAS mutation is another oncogenic mutation frequently observed in AML, and common downstream signaling pathways of both oncogenes that drive proliferation and survival of AML are phosphoinositide 3-kinase (PI3K)/Akt and MEK/ERK cascades [43]. The gene discussed is AKT1; the disease is acute myeloid leukemia.